Thematic Pulse
Healthcare’s technology inflection point
Healthcare has long been driven by scientific breakthroughs, but a growing number of advances are now emerging from the intersection of medicine and technology. Artificial intelligence is helping researchers identify potential drug targets, genetic data is enabling more personalised treatments, and digital tools are changing how healthcare professionals diagnose and treat disease. At the same time, technologies originally developed for consumer applications are beginning to find their way into hospitals and operating rooms.
Personalised medicine reaches an important milestone
One of the clearest examples of technology’s growing role in healthcare is personalised cancer treatment. In August 2026, a leading pharmaceutical company and an mRNA biotechnology specialist reported positive Phase 3 results for an investigational personalised cancer therapy used alongside an established immunotherapy in patients with advanced melanoma following surgery.
The treatment is notable because it is designed specifically for each patient. Genetic analysis of an individual’s tumour is combined with computational tools to identify potential targets for the immune system. This information is then used to create a personalised mRNA treatment tailored to the patient.
The approach represents a move away from the traditional model in which every patient receives the same treatment. Instead, advances in genetic sequencing, data analysis, and manufacturing are creating the possibility of therapies designed around individual biology. Important questions remain, including long-term survival outcomes and regulatory approval, but the positive Phase 3 data nevertheless mark a significant step forward for personalised medicine.
AI’s next test: drug discovery
Drug development has traditionally been a slow, expensive and uncertain process. AI developers hope that advanced computing can help researchers identify biological targets, analyse vast datasets, and design potential medicines more efficiently. In July 2026, an AI-focused biotechnology company began a Phase 3 trial for an experimental treatment for idiopathic pulmonary fibrosis, with AI playing a key role in both identifying the target and designing the molecule. The programme progressed from target identification to drug-candidate selection in around eighteen months, an unusually rapid timeframe.
Yet speed alone is not enough. The central question is whether AIdesigned molecules ultimately become safe, effective, and commercially successful medicines. While more than one hundred AI-enabled drug candidates have now entered clinical trials, most remain in the earlier stages of development. Encouragingly, the pipeline is becoming real, but definitive clinical proof is still emerging.
The operating room becomes connected
Technology is also beginning to reshape healthcare delivery itself. In September 2026, a medicaltechnology company announced the first surgical procedure using a mixed-reality visualisation system developed in partnership with a major consumer-technology company. The platform allows surgeons to view imaging data, surgical video and other information within their field of vision while maintaining awareness of the operating room around them.
The concept is simple but potentially powerful. Instead of dividing attention between multiple screens, surgeons can access relevant information in a single integrated environment. Although it remains early in its development cycle, the technology represents one of the first examples of spatial computing entering a regulated healthcare setting.
More broadly, it highlights an important trend: the line between healthcare and the technology sector is becoming increasingly blurred. Future innovation may depend on partnerships that combine medical expertise and regulatory knowhow with advances in computing, software and hardware.
A broader technological transformation
Beyond these headline examples, evidence of healthcare’s technological transformation can be seen across multiple areas. Studies of AI-supported mammography have shown both reduced radiologist workloads and improved cancer-detection rates. Gene therapy is demonstrating the potential to address the underlying causes of conditions previously managed through supportive care. Meanwhile, robotic blood-draw technology illustrates how automation could help healthcare providers address repetitive tasks and workforce shortages.
Taken together, these developments suggest that healthcare is undergoing a broad digital transformation rather than experiencing a single breakthrough. Technology is increasingly touching every stage of the healthcare pathway, from drug discovery and diagnostics to treatment, workflow management and ongoing patient monitoring.
Technology is moving from promise to proof
Recent developments across healthcare show how broad this transformation is becoming:
63.6% lower radiologist workload
A prospective study of AI-supported mammography showed that technology can potentially reduce the amount of routine work required from radiologists.
15% higher cancer detection
The same study reported higher cancer detection compared with standard reading.180% of evaluable patients improved their hearing
A gene therapy for inherited hearing loss demonstrated how genetic medicine may potentially treat the underlying cause of diseases previously managed mainly through devices or supportive care.2
Robotics reaches routine healthcare tasks
FDA-authorized robotic blood-draw technology illustrates how automation could eventually help address repetitive tasks and shortages of healthcare workers.3What this means for investors
The investment implications extend well beyond a narrow group of “AI healthcare” companies. Potential beneficiaries include pharmaceutical and biotechnology firms, diagnostics providers, healthcare software companies, medical-device manufacturers and businesses supplying the infrastructure that supports them.
Importantly, innovation is not confined to smaller biotechnology firms. Large pharmaceutical and medical-technology companies may also be well positioned as they can combine new technologies with extensive scientific expertise, regulatory experience, manufacturing capabilities, and established healthcare relationships. In many cases, the value of a technological breakthrough increases when it is paired with these existing strengths.
While investors must distinguish carefully between technological possibility and validated clinical value, the direction of travel is becoming increasingly clear. AI may help generate drug candidates and new computing platforms may improve clinical workflows, but success will still depend on regulatory approval, manufacturing, reimbursement, and real-world adoption. For companies that can successfully navigate these hurdles, however, technology has the potential to unlock meaningful competitive advantages and longterm growth opportunities.
1 Elías-Cabot, G., et al., “AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial,” Nature Medicine, 19 March 2026.
2 Agence France-Presse, “First gene therapy to treat hearing loss okayed,” reporting on FDA accelerated approval and associated clinical trial data, 24 April 2026.
3 U.S. Food and Drug Administration, press release, “FDA Authorizes First-of-Its-Kind Robotic Blood Draw Device,” 19 August 2026.
